Patrizia Nanni

ORCID: 0000-0001-5319-0803
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immunotherapy and Immune Responses
  • Monoclonal and Polyclonal Antibodies Research
  • Virus-based gene therapy research
  • Sarcoma Diagnosis and Treatment
  • HER2/EGFR in Cancer Research
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cancer Cells and Metastasis
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • vaccines and immunoinformatics approaches
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Treatments and Mutations
  • Cell Adhesion Molecules Research
  • Epigenetics and DNA Methylation
  • RNA Interference and Gene Delivery
  • Viral Infectious Diseases and Gene Expression in Insects
  • MicroRNA in disease regulation
  • Radiopharmaceutical Chemistry and Applications
  • Estrogen and related hormone effects
  • Glycosylation and Glycoproteins Research
  • Herpesvirus Infections and Treatments
  • Cancer Genomics and Diagnostics
  • T-cell and B-cell Immunology
  • Cancer-related Molecular Pathways

University of Bologna
2015-2025

University of Catania
2010

Istituto Ortopedico Rizzoli
2000-2009

Institute of Cancer Research
2009

Center for Cancer Research
1992-2005

Cancer Research Center
2000

Max Delbrück Center
1999

University of Chieti-Pescara
1998

Centro Interuniversitario di Ricerca Per lo Sviluppo sostenibile
1991-1994

University of Genoa
1993

Ten years after the publication of position paper "The hallmarks cancer" (Hanahan and Weinberg Cell 100:57-70, 2000), it has become increasingly clear that mutated cells on their way to giving rise a tumor have also learn how thrive in chronically inflamed microenvironment, evade immune recognition, suppress reactivity. Genetic molecular definition these three cancer offers opportunity deploy specific countermeasures reverse situation favor system and, eventually, patient. This new...

10.1007/s00262-010-0968-0 article EN cc-by-nc Cancer Immunology Immunotherapy 2011-01-25

Abstract The ability of vaccination with plasmids coding for the extracellular and transmembrane domain product transforming rat Her-2/neu oncogene (r-p185) to protect against r-p185+ transplantable carcinoma (TUBO) cells mammary carcinogenesis was evaluated. In normal BALB/c mice, DNA elicits anti-r-p185 Ab, but only a marginal CTL reactivity, protects TUBO cell challenge. Massive reactive infiltration is associated rejection. mice transgenic gene (BALB-neuT), lower Ab response, no activity...

10.4049/jimmunol.165.9.5133 article EN cc-by The Journal of Immunology 2000-11-01

The ability of interleukin (IL)-12 to prevent tumors when administered individuals with a genetic risk cancer was studied in two lines transgenic mice expressing rat HER-2/neu oncogene the mammary gland. Female BALB/c (H-2d) carrying activated HER-2/ neu show no morphological abnormalities gland until 3 wk age. They then progress through atypical hyperplasia situ lobular carcinoma and at 33 age all 10 glands display invasive carcinomas. Adult FVB (H-2q) protooncogene develop carcinomas...

10.1084/jem.188.3.589 article EN The Journal of Experimental Medicine 1998-08-03

Transgenic Balb/c mice expressing the transforming rat HER-2/neu oncogene develop early and multifocal mammary carcinomas. Within first 5 months of life tissue-specific expression causes a progression in all their 10 glands from atypical hyperplasia to invasive carcinoma. It was previously observed that chronic administration interleukin (IL)-12 increased tumor latency, but every mouse eventually succumbed multiple A significant improvement prevention sought by administering allogeneic...

10.1084/jem.194.9.1195 article EN The Journal of Experimental Medicine 2001-10-29

Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% invasive breast cancers. Monoclonal antibody therapy is effective treating HER2-driven mammary carcinomas, but its utility limited by high costs, side effects and development resistance. Active vaccination may represent a safer, more cheaper alternative, although the induction strong durable autoantibody responses hampered immune-tolerogenic mechanisms. Using novel virus-like particle (VLP) based vaccine...

10.1080/2162402x.2017.1408749 article EN OncoImmunology 2017-11-29

Abstract Purpose: Small-molecule insulin-like growth factor-I receptor (IGF-IR)-specific tyrosine kinase inhibitors have been recently proposed as clinically viable approaches to impair IGF-IR functions. NVP-AEW541 seems one of the most promising agents. In this article, we point out its effects against migration, metastasis, vasculogenicity, and angiogenesis Ewing's sarcoma cells. Experimental Design: vivo effectiveness was analyzed TC-71 bone metastasis after cell inoculation in athymic...

10.1158/1078-0432.ccr-06-1518 article EN Clinical Cancer Research 2007-02-15

The oncogenic versus suppressor roles of mitochondrial genes have long been debated. Peculiar features genetics such as hetero/homoplasmy and mutation threshold are seldom taken into account in this debate. Mitochondrial DNA (mtDNA) mutations generally claimed to be protumorigenic, but they also hallmarks mostly benign oncocytic tumors wherein help reduce adaptation hypoxia by destabilizing hypoxia-inducible factor-1α (HIF1α). To determine the influence a disassembling mtDNA its on...

10.1158/0008-5472.can-11-1042 article EN Cancer Research 2011-08-19

Mitochondrial DNA mutations are currently investigated as modifying factors impinging on tumor growth and aggressiveness, having been found in virtually all cancer types most commonly affecting genes encoding mitochondrial complex I (CI) subunits. However, it is still unclear whether they exert a pro- or anti-tumorigenic effect. We here analyzed the impact of three homoplasmic mtDNA (m.3460G>A/MT-ND1, m.3571insC/MT-ND1 m.3243A>G/MT-TL1) osteosarcoma progression, chosen since induce different...

10.1093/hmg/ddt533 article EN Human Molecular Genetics 2013-10-24

In vivo studies of the metastatic process are severely hampered by fact that most human tumor cell lines derived from highly tumors fail to consistently metastasize in immunodeficient mice like nude mice. We describe a model system based on double knockout mouse, Rag2−/−;Il2rg−/−, which lacks T, B and NK activity. this HER-2+ breast cancer cells displayed their full multiorgan potential, without need for selections or additional manipulations system. Human MDA-MB-453 BT-474 injected into...

10.1371/journal.pone.0039626 article EN cc-by PLoS ONE 2012-06-21

Abstract Background Aerobic glycolysis, namely the Warburg effect, is main hallmark of cancer cells. Mitochondrial respiratory dysfunction has been proposed to be one major causes for such glycolytic shift. This hypothesis revisited as tumors appear undergo waves gene regulation during progression, some which rely on functional mitochondria. In this framework, role mitochondrial complex I still debated, in particular with respect effect DNA mutations metabolism. The aim work provide proof...

10.1186/2049-3002-1-11 article EN cc-by Cancer & Metabolism 2013-03-18

Abstract A splice isoform of the HER2 receptor that lacks exon 16 (d16HER2) is expressed in many HER2-positive breast tumors, where it has been linked with resistance to HER2-targeting antibody trastuzumab, but impact d16HER2 on tumor pathobiology and therapeutic response remains uncertain. Here, we provide genetic evidence transgenic mice expression sufficient accelerate mammary tumorigenesis improve trastuzumab. comparative analysis effector signaling pathways activated by wild-type...

10.1158/0008-5472.can-14-0983 article EN Cancer Research 2014-08-28

Fully retargeted oncolytic herpes simplex viruses (o-HSVs) gain cancer-specificity from redirection of tropism to cancer-specific receptors, and are non-attenuated. To overcome the hurdles systemic delivery, enable (o-viruses) reach metastatic sites, carrier cells being exploited. Mesenchymal stromal (MSCs) were never tested as carriers o-viruses, given their scarse-null expression receptors. We report that MSCs different sources can be forcedly infected with a HER2-retargeted HSV. Progeny...

10.18632/oncotarget.5793 article EN Oncotarget 2015-09-27

Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice. Most of them gain cancer-specificity from deletions/mutations genes that counteract the host response, grow selectively cancer cells defective anti-viral response. Because deletions/mutations, they are frequently attenuated or over-attenuated. We developed next-generation oHSVs, which carry no deletion/mutation, specific retargeting to tumor cell receptors—e.g. HER2 (human epidermal growth factor...

10.1371/journal.ppat.1007209 article EN cc-by PLoS Pathogens 2018-08-06

Abstract Standard therapy of osteosarcoma (OS) and Ewing sarcoma (EW) rests on cytotoxic regimes, which are largely unsuccessful in advanced patients. Preclinical models needed to break this impasse. A panel patient-derived xenografts (PDX) was established by implantation fresh, surgically resected NSG mice. Engraftment obtained 22 61 OS (36%) 7 29 EW (24%). The success rate establishing primary cell cultures from lower than the percentage PDX engraftment mice, whereas reverse observed for...

10.1038/s41598-019-48634-y article EN cc-by Scientific Reports 2019-08-21
Coming Soon ...